'김갑성' 기자의 전체기사
-
Pioneering Freeze-Dried Technology in Vietnam: Nature Fo…
HO CHI MINH CITY, Vietnam, Aug. 13, 2025 -- Amid rapid urbanization and an increasingly fast-paced lifestyle, Vietnam's ready-to-eat (RTE) food market is witnessing remarkable growth. In 2024, the market value reached approximately USD 430 million and is projected to nearly triple to USD 1.28 billion by 2031, with a compound annual growth rate (CAGR) of 16.8% (BlueWeave Consulting). This surge underscores a clear consumer trend: the demand for quick meal solutions that still meet high standards of nutrition, quality, and safety. Yet, convenience alone is not enough. Flavor, nutrition,
- 김갑성 기자
- 2025-08-13 16:41
-
Avive Health to host Queensland's first Empax clinic in landma…
BRISBANE, Australia, Aug. 13, 2025 -- Avive Health ("Avive"), an Australian-owned private mental health provider, has announced a major national partnership with Emyria Limited (ASX: EMD), marking a significant milestone in the evolution of evidence-based, reimbursable mental health treatment across Australia. Avive delivers inpatient, day program and outpatient psychiatric care across Australia's eastern seaboard, with a strong focus on trauma-informed, patient-centred models that combine clinical rigor with therapeutic innovation. The organisation supports voluntary adult patients th
- 김갑성 기자
- 2025-08-13 15:40
-
Daewoong Therapeutics Microneedle Patch Achieves Bes…
More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new global benchmark A potential game changer that addresses both the pain of injections and the low efficiency of oral formulations In the obesity treatment market, delivery technology is expected to be the decisive factor shaping future leaders SEOUL, South Korea, Aug. 13, 2025 -- Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) announced that t
- 김갑성 기자
- 2025-08-13 15:36
-
Hospital Management Asia 2025: Shaping the Future of Asian…
HO CHI MINH CITY, Vietnam, Aug. 13, 2025 -- Hospital Management Asia (HMA), the region's premier annual event for hospital management and healthcare, is set to officially take place at GEM Center, Ho Chi Minh City. This year's conference, organised by Clarion Events Pte Ltd, will gather over 100 speakers from 15 countries and territories, alongside hundreds of hospital leaders, medical professionals, and healthcare organizations from across the region and beyond. From Healthcare System Reform to Medical Tourism Under the theme "Quality, Experience & Leadership i
- 김갑성 기자
- 2025-08-13 15:19
-
Prince Court Medical Centre Strengthens Malaysia's Position…
KUALA LUMPUR, Malaysia, Aug. 13, 2025 -- Prince Court Medical Centre has placed Malaysia firmly on the global medical tourism map by successfully performing the country's first Kelly procedure, an advanced reconstructive surgery for rare congenital urological conditions. On 11 August, a two-year-old boy from Indonesia underwent the pioneering surgery, jointly led by Dr. Roger Anthony Idi, Consultant Urologist at Prince Court, and Professor Imran Mushtaq, a world-renowned paediatric urologist recognised internationally for his expertise in complex reconstructive surgery for rare
- 김갑성 기자
- 2025-08-13 15:16
-
정밀 의료, 한국에서 60조원의 경제 효과 및 치료 패러다임 전환 예고
[ 메디채널 김갑성 기자 ] 정밀 의료 접근성 향상 위해 규제 및 시스템적 개선 필요 서울, 대한민국, 2025년 8월 13일 -- 글로벌 전략 컨설팅 기업 'L.E.K. 컨설팅'이 오늘 발표한 백서 '정밀 의료 사례 연구 보고서(On the Cusp of a Cure)'에 따르면, 정밀 의료 시대가 본격화되면 향후 10년간 한국에서 약 60조 원의 경제 효과와 보건의료 전반에 걸친 사회•경제적 가치가 실현될 것으로 전망된다. 정밀 의료는 기존의 획일적인 치료 방식과 달리 환자 개개인의 유전적 정보와 질병 특성에 기반해 맞춤형 치료를 제공하는 새로운 접근 방식으로, 질환에 대해 근본적인 치료 가능성을 제시한다. 유전자 치료제, 표적 항체 치료제, 약물-기기 복합 치료제, 정밀 진단 기술이 정밀 의료의 대표적인 핵심 기술이다. 이번 보고서는 글로벌 컨설팅 회사 L.E.K. 컨설팅과 아시아태평양 지역 16인의 전문가 자문위원회가 함께 개발한 것으로, '전체 시스템 이익 모델링(whole system benefits modelling)'을 활용해 한국에서 정밀 의료가 가져올 경제 및 보건의료적 효과를 분석했다.
- 김갑성 기자
- 2025-08-13 10:51
-
KBP's Contest of Injunction Obtained by Novo Nordisk Continu…
SINGAPORE, Aug. 13, 2025 -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a further decision by the Singapore International Commercial Court (the "Court") to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang"), in support of arbitration proceedings respectively commenced by the Company and by Novo Nordisk A/S ("Novo Nordisk"). Following the Court's judgment today, the validity of the injunction application sought by Novo Nordisk will be determined via the arbitral
- 김갑성 기자
- 2025-08-13 09:44
-
Second heartbeat
BEIJING, Aug. 13, 2025 -- A news report from chinadaily.com.cn In this documentary, three patients suffered from advanced heart failure share their stories of how China's independently-developed non-contact full maglev artificial heart brought hope to their lives. Click to learn more!
- 김갑성 기자
- 2025-08-13 09:34
-
Willog Partners with Republic of Korea Army to Modernize Milita…
SEOUL, South Korea, Aug. 12, 2025 -- Willog, a leading provider of IoT and AI-powered supply chain intelligence solutions, today announced the signing of a Memorandum of Understanding (MOU) with the Republic of Korea (R.O.K.) Army Consolidated Supply Depot(Army Logistics Command). The partnership marks a significant step in the South Korean Army's ongoing digital transformation. Under the agreement, Willog will provide its cutting-edge technology and expertise to support the digital transformation of the Army's supply chain. This collaboration will involve joint research, techn
- 김갑성 기자
- 2025-08-13 08:00
-
Ascletis Announces ASC47, a Muscle-Preserving Weight Los…
[ 메디채널 김갑성 기자 ] - The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy. - ASC47 low dose in combination with tirzepatide demonstrated statistically significantly greater increase in efficacy than ASC47 low dose in combination with semaglutide, 87% vs 55%, respectively, in the DIO mouse model. - The combination of ASC47 low dose with tirzepatide also restored the body composition of obese mice to the level of healthy non-obese mice. A
- 김갑성 기자
- 2025-08-13 07:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-08-20_WED
- Global Times: Development opportunities, potential and advantages should be better used 23:58
- First IPO Under GIFT City's IFSC Regime - DRHP Filed; Executive Education Platform Leads the Charge 22:19
- Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning 22:14
- TGE alongside with AMTD Obtain Successful Court Decisions against Unauthorised and Infringing Activities in Austria 21:55
- Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year 21:41
- FOSSIL AND 2025-2026 GLOBAL BRAND AMBASSADOR NICK JONAS RELEASE EXCLUSIVE "MACHINE LUXE" CAPSULE 21:00
- IBM and NASA Release Groundbreaking Open-Source AI Model on Hugging Face to Predict Solar Weather and Help Protect Critical Technology 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 08월 21일 01시 40분